Today: 20 March 2026
Subscribe
Browse Category

OTC:NRXS 24 October 2025

NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis announced FDA 510(k) clearance for its PENFS device to treat adult functional dyspepsia on Oct. 24, marking the first approved therapy for this condition. NRXS shares rose to $3.82 on Oct. 23 and traded higher pre-market after the news. The company recently raised $5 million and expanded insurance coverage to 53 million lives. Q2 revenue grew 46% year-over-year; analyst sentiment remains mixed.
24 October 2025
··

Stock Market Today

  • JD Wetherspoon Shares Drop 10% Amid Earnings Warning but Show Strong Sales Growth
    March 20, 2026, 12:52 PM EDT. JD Wetherspoon's (LSE:JDW) share price fell about 10% after the mid-year results for the 26 weeks ended Jan 25 revealed a 32.7% drop in earnings per share (EPS) to 18.7p. The company cited pressure from higher taxes, wages, and energy costs, warning profits may fall below market expectations. Despite this, like-for-like sales rose 4.8%, and revenue increased 5.7%. The pub chain outperformed the industry for the 42nd consecutive month with 3.2% sales growth, and its shares now trade at a price-to-earnings ratio of 10.8, below its five-year average of 15.3. Chairman Tim Martin highlighted rising operational costs but stopped short of confirming a full-year profit decline, suggesting the price dip might be an overreaction.
Go toTop